CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2023 and reviewed recent business highlights. “2023 was a year of strong execution at Alnylam. We delivered robust product revenue growth across our four wholly-owned commercial medicines, with $1.24 billion in global net product revenues, and achieved over 5,000 patients now being ...

Cavan Images One niche area of biotech that I've followed closely over the past several years has been the treatment and pipeline for transthyretin amyloidosis (ATTR). ATTR is a rare genetic disease where a mutation in the TTR gene causes the liver to produce a misfolded protein called transthyretin, which can build up in the body resulting in polyneuropathy and cardiomyopathy. This progressive disease is often diagnosed later in life only after patients start to experience a high disease burden, which incl ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, said today that Chief Executive Officer Yvonne Greenstreet has been selected as the 2024 Woman of the Year by the Healthcare Businesswomen’s Association (HBA). The announcement was made last evening at the J.P. Morgan Healthcare Conference in San Francisco. Yvonne will be recognized at HBA’s 34th annual Woman of the Year event on May 10 in New York City. The HBA Woman of the Year award ...

Alnylam Pharmaceuticals (ALNY) reported preliminary full-year 2023 net product revenues of $1.24 billion, representing 39% growth at a constant exchange rate. The Zacks Consensus Estimate for the same is pegged at $1.83 billion.The company’s net product revenues comprise sales of its four marketed products, such as Onpattro, Amvuttra, Givlaari and Oxlumo.In 2023, preliminary global net product revenues for Onpattro and Amvuttra were approximately $355 million and $558 million, respectively, representing a 4 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2023 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches. Preliminary Fourth Quarter and Full Year 2023 Commercial and Financial Performance* Total TTR: ONPATTRO® (patisiran) & AMVUTTRA® (vutrisiran) Preliminary global net product rev ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President-Investor Relations and Corporate Communication Yvonne Greenstreet - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Pushkal Garg - Chief Medical Officer and EVP, Development & Medical Affairs Jeff Poulton - Chief Financial Officer Conference Call Participants Ritu Baral - TD Cowen Paul Matteis - Stifel Lisa Munro - RBC El ...

Nathan (USA) Diagnosed with AHP Third Quarter 2023 Financial Results November 2, 2023 1 © 2023 Alnylam Pharmaceuticals, Inc. Agenda Welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq Stock Market LLC For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O ...

Nathan (USA) Diagnosed with AHP Second Quarter 2023 Financial Results August 3, 2023 1 © 2023 Alnylam Pharmaceuticals, Inc. Agenda Welcome ...

Financial Data and Key Metrics Changes - Total product revenues for Q2 2023 were $306 million, representing a 43% year-over-year growth compared to Q2 2022 [27] - Gross margin on product sales was 75%, a 9% decrease compared to Q2 2022, primarily due to fees associated with canceling manufacturing commitments for ONPATTRO [28] - Non-GAAP operating loss for the quarter was $154 million, showing a $7 million improvement compared to Q2 2022 [30] Business Line Data and Key Metrics Changes - The TTR franchise achieved $224 million in global net product revenues for ONPATTRO and AMVUTTRA, representing a 46% growth year-over-year [10] - GIVLAARI and OXLUMO together delivered $82 million in combined product sales during Q2, representing a 37% growth compared to Q2 2022 [13] Market Data and Key Metrics Changes - In the US, combined sales of ONPATTRO and AMVUTTRA increased by 72% year-over-year, marking the fourth consecutive quarter of TTR growth exceeding 70% [11] - AMVUTTRA demand in Japan is particularly encouraging, with new patient growth driven by switches from tafamidis and patients naive to therapy [10] Company Strategy and Development Direction - The company entered into a strategic partnership with Roche for the development and commercialization of zilebesiran, aiming to disrupt the global treatment paradigm for hypertension [6] - The company is focused on achieving its Alnylam P5x25 goals, positioning itself as a top-tier biotech company developing transformative medicines for rare diseases [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming catalysts, including the initial data from the KARDIA Phase 2 program and the potential launch of ONPATTRO for ATTR amyloidosis with cardiomyopathy [7] - The management highlighted the importance of maintaining high ethical standards in business conduct, especially in interactions with healthcare providers and patients [6] Other Important Information - The US Attorney's Office for the District of Massachusetts concluded its case regarding the marketing and promotion of ONPATTRO with no action taken [6] - Akshay Vaishnaw transitioned to the role of Chief Innovation Officer, focusing on the future of the R&D engine [8] Q&A Session Summary Question: Any updated thoughts on the upcoming AdCom ONPATTRO and ATTR CM? - Management is actively preparing for the advisory committee and believes the focus will be on the clinical meaningfulness of changes in the six-minute walk test and KCCQ [35] Question: Clarification on the Roche deal for zilebesiran? - The deal includes $310 million upfront and $365 million in potential development milestones, with Roche covering 60% of development costs [40] Question: Consideration by the FDA regarding the PDUFA date for ONPATTRO? - Management anticipates the PDUFA date of October 8th and is working towards that, with no changes communicated by the FDA at this time [44] Question: Timing and reasoning behind Akshay's role change? - The transition to Chief Innovation Officer allows for a more focused role in driving R&D success, with no specific reason for the timing [51] Question: Details on the expanded access program for patisiran? - The program enrolled 200 patients rapidly, highlighting the significant demand for alternative therapies for patients experiencing progression [69]